Literature DB >> 30150467

Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo Simulation.

Alan E Gross1,2, Hongmei Xu3, Diansong Zhou3, Nidal Al-Huniti3.   

Abstract

The manufacturer-recommended aztreonam dosing for patients with creatinine clearance values of <10 ml/min/1.73 m2 is complex. It is not known whether simpler posthemodialysis dosing administered once daily or thrice weekly can reliably achieve pharmacodynamic goals. We found that 1 or 2 g administered once daily after hemodialysis had >90% probability of target attainment up to MICs of 4 or 8 mg/liter, respectively. Thrice-weekly dosing should generally be avoided, except in nonsevere infections with MICs of ≤0.5 mg/liter.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Monte Carlo simulation; aztreonam; end-stage renal disease; kidney dysfunction; pharmacodynamics; renal failure

Mesh:

Substances:

Year:  2018        PMID: 30150467      PMCID: PMC6201116          DOI: 10.1128/AAC.01066-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Single-dose pharmacokinetics of aztreonam in healthy volunteers and renal failure patients.

Authors:  M A el Guinaidy; S Nawishy; M Abd el Bary; M S Sabbour
Journal:  J Chemother       Date:  1989-06       Impact factor: 1.714

Review 3.  Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection.

Authors:  Michael Trang; Michael N Dudley; Sujata M Bhavnani
Journal:  Curr Opin Pharmacol       Date:  2017-11-10       Impact factor: 5.547

4.  Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.

Authors:  P F Smith; C H Ballow; B M Booker; A Forrest; J J Schentag
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

5.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors:  Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.

Authors:  N Al-Huniti; D Zhou; H Xu; S Aksenov; K H Bui; R Fox; G Helmlinger; D Stanski
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

Review 7.  Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Authors:  Michael N Dudley; Paul G Ambrose; Sujata M Bhavnani; William A Craig; Mary Jane Ferraro; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2013-01-18       Impact factor: 9.079

8.  Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.

Authors:  J C Mihindu; W M Scheld; N D Bolton; D A Spyker; E A Swabb; W K Bolton
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Safety profile of aztreonam in clinical trials.

Authors:  T J Newman; G R Dreslinski; S S Tadros
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec

10.  Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations.

Authors:  M A Marx; R F Frye; G R Matzke; T A Golper
Journal:  Am J Kidney Dis       Date:  1998-09       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.